Limitless X enters binding LOI to acquire 60% of Ding Easy AI for $9M in stock

Limitless X Holdings Inc.

Bodycor, subsidiary of Limitless X, to acquire 60% of Ding Easy AI at $15M pre-money valuation; consideration of $9M in LIMX restricted stock.
Ding is controlled by Daniel Sanders, also President of Limitless X's subsidiary; transaction approved by Audit Committee as related-party.
Up to $1.75M growth capital from Bodycor, with $750K in tranches and $1M contingent on revenue/user milestones.
Bodycor gets call option to acquire remaining 40% upon Ding reaching $40M valuation, for $16M in stock.
Exclusivity period of 120 days; definitive agreements to follow.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Limitless X Holdings Inc. entered into Binding Letter of Intent with Ding Easy AI, LLC and the equityholders of Ding valued at an aggregate value of nine million dollars ($9,000,000) (effective 2026-01-26).

Action: entry
Agreement: equity purchase
Counterparty: Ding Easy AI, LLC and the equityholders of Ding
Value: an aggregate value of nine million dollars ($9,000,000)
Effective: 2026-01-26

Exact text from the filing

On January 26, 2026, Bodycor, Inc., a Nevada corporation (“Bodycor”), and Limitless X Holdings Inc., a Delaware corporation (the “Company”, which is the issuer of the Common Stock described herein), entered into a Binding Letter of Intent (the “LOI”) with Ding Easy AI, LLC, a Delaware limited liability company (“Ding”), and the equityholders of Ding (“Ding Owners”).

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

Limitless X Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-005710

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.